Interpace Biosciences, Inc.
IDXGD
$6.98
-$0.02-0.29%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -20.48% | -24.90% | -17.47% | -6.06% | 9.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.48% | -24.90% | -17.47% | -6.06% | 9.78% |
| Cost of Revenue | -22.92% | -21.40% | -14.13% | 3.98% | 13.00% |
| Gross Profit | -19.03% | -26.86% | -19.37% | -11.31% | 7.95% |
| SG&A Expenses | -18.10% | -18.66% | -14.01% | 0.40% | 10.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.22% | -19.77% | -13.91% | 2.00% | 11.38% |
| Operating Income | -22.11% | -47.85% | -34.55% | -40.24% | 0.73% |
| Income Before Tax | -17.70% | -60.35% | -45.70% | -42.02% | 1.65% |
| Income Tax Expenses | -149,114.29% | -116,355.56% | -530,350.00% | -105.88% | -17.65% |
| Earnings from Continuing Operations | 413.21% | 205.03% | 259.69% | -41.87% | 1.72% |
| Earnings from Discontinued Operations | -47.50% | -66.80% | -67.62% | -61.08% | -48.15% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 435.65% | 209.50% | 266.68% | -44.65% | -0.20% |
| EBIT | -22.11% | -47.85% | -34.55% | -40.24% | 0.73% |
| EBITDA | -19.38% | -44.92% | -31.83% | -37.55% | -0.14% |
| EPS Basic | 475.66% | 219.04% | 290.28% | -51.95% | -11.18% |
| Normalized Basic EPS | -35.14% | -56.72% | -28.69% | -35.40% | 11.33% |
| EPS Diluted | 43.95% | -44.07% | -46.12% | -82.81% | -41.09% |
| Normalized Diluted EPS | -65.92% | -85.47% | -85.02% | -91.60% | -54.45% |
| Average Basic Shares Outstanding | 236.32% | 104.94% | 0.85% | 1.17% | 1.42% |
| Average Diluted Shares Outstanding | 28.45% | 1.48% | 39.08% | 524.26% | 394.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |